board of director
United States Minor Outlying Islands
Paul received his undergraduate degree from Wesleyan University, his M.D. with distinction in research from the University of Rochester, and completed residency training in Combined Internal Medicine and Pediatrics at Emory University. He completed two fellowships: Adult Endocrinology Diabetes and Metabolism at the University of Pittsburgh Medical Center as well as Pediatric Endocrinology at the Children’s Hospital of Pittsburgh. Paul is one of a handful of Endocrinologists to be a Diplomate of 2 specialty, and 2 subspecialty boards. He practiced Adult and Pediatric Endocrinology for 6 years, and served as a Clinical Associate Professor, UNC Departments of Internal Medicine and Pediatrics. Paul has over 20 years of work experience in Endocrinology and Diabetes, including over 10 years of Clinical Development experience in the pharmaceutical industry where he assumed roles of increasing programmatic and strategic responsibility in phases I to IV of Clinical Development at GlaxoSmithKline, Merck KGaA, Bristol-Myers Squibb & Co, and was the Chief Medical Officer at the Juvenile Diabetes Research Foundation. In his most recent position at Quintiles he served as Vice President, Therapeutic Strategy Head of the Cardiovascular and Metabolic Therapy Area, Chair of the Diabetes Center of Excellence, and Regional Chief Medical Officer of North America. Paul joined Lexicon Pharmaceuticals in 2013 as Vice President, Clinical Development to lead the development programs for Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor being developed by Lexicon as adjunct to insulin therapy in type 1 diabetes, and by partnership with Sanofi for the treatment of type 2 diabetes.